权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Nezavist a Novel Molecule for Treatment of Alcohol Use Disorder

Nezavist 是一种治疗酒精使用障碍的新型分子

基本信息

批准号：
10321981
负责人：
Boris Tabakoff
金额：
$ 12.44万
依托单位：
LOHOCLA RESEARCH CORPORATION
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-09-25 至 2021-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10321981
关键词：
Abstinence Accidents Achievement Acute Address Affect Age Alcohol consumption Alcohol dependence Alcohols Anesthesia and Analgesia Animals Applications Grants Binding Sites Biological Availability Blood Brain Canis familiaris Cardiovascular system Characteristics Chemicals Chronic Clinical Clinical Trials Clinical Trials Design Collaborations Consumption Cyclic GMP Data Development Dosage Forms Dose Drug Evaluation Drug Kinetics Drug usage Enteric Nervous System Evaluation Research Excipients Exclusion Excretory function FDA approved Food Formulation Funding Future GABA-A Receptor Goals Grant Health Health Care Costs Heavy Drinking Human Hydrolysis In Vitro Individual Industry Investigational Drugs Life Style Maintenance Measures Medical Care Costs Metabolism Miniature Swine Modeling Monitor Monkeys Mus National Institute on Alcohol Abuse and Alcoholism Neurotransmitter Receptor Oral Oral Administration Oryctolagus cuniculus Parabens Patients Pharmaceutical Preparations Pharmacodynamics Pharmacotherapy Phase Phase I Clinical Trials Placebos Population Powder dose form Primary Care Physician Principal Investigator Procedures Process Production Productivity Property Rattus Regulation Relapse Reporting Research Resources Rodent Role Safety Series Shipping Small Business Innovation Research Grant Societies Solid Solubility Suspensions Technology Testing Therapeutic Therapeutic Index Tissues Toxic effect Toxicokinetics Toxicology Treatment Failure United States Food and Drug Administration Vagus nerve structure Work World Health Organization Writing absorption addiction alcohol abuse therapy alcohol use disorder arm base carboxylesterase clinical toxicology cost craving crystallinity design dosage economic cost experimental study human tissue in vivo meetings melting metabolic abnormality assessment metabolic profile microbiome nonhuman primate novel parent grant phase 1 study phase 1 testing phase 2 study phase I trial pre-clinical preclinical study prevent psychosocial respiratory safety study scale up

项目摘要

Abstract for Supplement Application The ultimate goal for our original project was to complete the proof-of-concept work, and the multitude of pharmacodynamic, pharmacokinetic, toxicokinetic, safety, and toxicology studies required by the FDA to apply for an IND. We are fully satisfied that we have generated a new chemical entity that acts at a novel binding site on the GABA-A receptor and acts in the gut by interacting with the microbiome, the enteric nervous system and the vagus nerve to block the significantly increased alcohol consumption in alcohol dependent animals after a period of forced abstinence (model of relapse). We have completed all non- clinical studies for an IND, and from our safety studies, we determined that our therapeutic dose in humans should be well below a dose that would produce any toxicity. The IND application is being written, but a critical issue remains to be addressed prior to IND submission. This issue centers on our plans to comply with the FDA Guidance for Industry “cGMP for Phase 1 Investigational Drugs.” This Guidance details the processes, controls, quality checks on purity and stability, and fidelity of dosage delivery for producing the dosage forms to be used in the Phase 1 trials. The data and information on the production and testing of the Phase 1 dosage forms must be included with the IND application. We have worked with Catalent Pharma in the past to develop materials for dosing animals and have engaged them to produce the dosage forms for humans. The development, production, and control of formulations for humans was not an aim of our original application and funds were not allocated for this task. We are now asking for supplemental funds in order to develop and produce the human dosage forms so that we can submit the IND application. Achievement of this milestone will start us on the path for successful completion of clinical trials and to bringing an effective medication to those suffering from AUD to return them to a non-addicted lifestyle. Abstract from the Parent Grant Application Alcohol Use Disorder affects 7.9% of the U.S. population ages 18 and older and costs society over $223 billion per year in direct medical costs, accidents, and lost productivity. Current pharmacotherapy is only modestly effective and must be used in conjunction with psychosocial treatment. Primary care physicians are ill equipped to provide the currently necessary range of therapy for treating AUD and the modest effects of therapy generate a significant number of treatment failures. We have generated a novel molecule with action directly at one of the major neurotransmitter receptors altered by chronic excessive consumption of alcohol. We have also demonstrated in two different models of relapse drinking by alcohol dependent animals that our medication can reduce or prevent such relapse. Our preliminary studies on the safety and metabolism of our compound in animals provide confidence that the compound will have a good therapeutic index in human clinical trials. Prior to embarking on the trials in humans we, however, need for our drug to be approved for an IND by the Food and Drug Administration. To be able to accomplish this milestone we are proposing a series of SBIR Phase I, IND enabling studies, which include the development of an oral formulation which will be attractive for use with humans. In these SBIR Phase I studies we will also establish the blood and brain levels of our drug after oral administration in the newly developed formulation. In the SBIR Phase II studies we will produce our drug under cGMP conditions and scale up production to meet future clinical trials. The Phase II SBIR studies will be fully focused on completing all of the FDA required studies for the IND, including complete studies of in vitro metabolism and metabolite identification, in vivo studies of Absorption, Distribution, Metabolism, and Excretion, complete studies on safety and toxicology (including toxicokinetics) in two species (rats and dogs). These studies will include escalating acute dose studies and sub-chronic and chronic studies of up to six months duration because we anticipate that human studies may include long term maintenance of patients on our medication. If an IND designation is obtained, we anticipate launching a Phase I human safety trial with an arm of this study aimed at a clinical measure of craving in alcohol-dependent subjects. If this grant is funded and our medication reaches human trials, we anticipate introducing a more efficacious and much more highly utilized medication to treat AUD.

补充申请摘要